A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer Full Text
Investigational New Drugs, 07/31/2012
Hartmann JT et al. – Matuzumab combined with paclitaxel was generally well tolerated in patients with advanced non–small cell lung cancer (NSCLC). There was some evidence of anticancer activity in relation to the matuzumab 800mg weekly dose.